TICKERNERD
Menu
ACRSACRSHealthcare · Biotechnology

ACRS Stock Forecast: Aclaris Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.32
−3.36% on the day

The 12 Wall Street analysts covering Aclaris Therapeutics, Inc. hold a median 12-month price target of $10 — +88.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$783.1M
Ticker Nerd rank
67 / 100
Median analyst target
$10
Analysts covering
12
Revenue$1.6M−8.3% y/y
Operating income−$23.9M
Net income−$21.5M
Free cash flow−$19.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.6%
1M
−10.1%
YTD
+76.7%
1Y
+170.1%
From 52W high
−18.6%
From 52W low
+193.9%
$1.81
$6.54
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aclaris Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Revisions
73
Value
64
Growth
54
Accruals
49
Size
48
Quality
44
Volatility
41
Issuance
39

Momentum (95): The shares have been drifting up relative to others.

Issuance (39): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26ACRSHigh $16Median $10Low $4

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $4Median $10High $16

The green dot is the last close — the median target sits +88.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026Canaccord GenuityInitiatesBuy$10
2 June 2026LifeSci CapitalInitiatesOutperform—
5 May 2026GuggenheimInitiatesBuy—
5 May 2026Piper SandlerMaintainsOverweight—
29 Apr 2026WedbushMaintainsOutperform—
16 Apr 2026OppenheimerInitiatesOutperform—
31 Mar 2026WedbushReiteratesOutperform—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
28 Jan 2026HC Wainwright & Co.ReiteratesBuy—
21 Jan 2026HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
10 July 2025Piper SandlerAssumesOverweight$6.00
25 June 2025HC Wainwright & Co.ReiteratesBuy—
28 May 2025WedbushInitiatesOutperform—
14 May 2025HC Wainwright & Co.MaintainsBuy—
9 May 2025ScotiabankMaintainsSector Outperform—
18 Mar 2025Cantor FitzgeraldReiteratesOverweight—
7 Mar 2025ScotiabankInitiatesSector Outperform—
23 Dec 2024HC Wainwright & Co.UpgradeBuy—
19 Nov 2024BTIGUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACRS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Aclaris Therapeutics, Inc. returned +170.1% against +17.5% for the S&P 500, dividends included.

ACRS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Oct 25Jan 26Apr 26Jul 26ACRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
3
Fundamentals

Aclaris Therapeutics, Inc. (ACRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.0×

Cheaper than 93% of US stocks

Price / sales
95.3×

Cheaper than 4% of US stocks

Price / book
6.0×

Cheaper than 17% of US stocks

EV / EBITDA
−8.1×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
−8.3%

Higher than 17% of US stocks

Earnings growth (YoY)
−8.3%

Higher than 28% of US stocks

Gross margin
10.8%

Higher than 10% of US stocks

Operating margin
−1469.5%

Higher than 5% of US stocks

Net margin
6.9%

Higher than 64% of US stocks

Returns & dividend
Return on equity
−59.1%

Higher than 19% of US stocks

Return on assets
−29.0%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aclaris Therapeutics, Inc. (ACRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aclaris Therapeutics, Inc. has a market value of $783.1M and an enterprise value of $693.4M.

  • Revenue in the twelve months to 30 June 2026: $8.2M. The latest quarter shrank 8.3% year on year.

  • Net income over the same four quarters: −$75.7M, a −921.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.58.

  • Free cash flow in the twelve months to 30 June 2026: −$62.2M.

  • Shares outstanding: 139.8M.

  • Trailing P/E: −10.0×; forward P/E: −6.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Aclaris Therapeutics, Inc. employs 69 people — $119K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ACRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACRSAclaris Therapeutics, Inc.$783.1M
67
CADLCandel Therapeutics, Inc.$772.4M
41
NVCTNuvectis Pharma, Inc.$756.3M
67
CLYMClimb Bio, Inc.$816.0M
60
GYREGyre Therapeutics, Inc.$750.3M
41
ANNXAnnexon, Inc.$746.9M
33
MNPRMonopar Therapeutics, Inc.$736.8M
57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aclaris Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACRS news & analysis

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

Aclaris Therapeutics announced that CEO Dr. Neal Walker will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 2:45 PM ET. The company is a clinical-stage biopharmaceutical firm developing product candidates for immuno-inflammatory diseases.

Why it matters — ACRS watchers would care because the CEO's scheduled appearance at a major healthcare conference provides an opportunity for the company to communicate its clinical-stage pipeline and strategy to investors and industry participants.

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Zacks Investment Research · 10 Aug 2026positive

The consensus price target for Aclaris (ACRS) implies a potential 69.2% upside, although the article notes this metric is of limited effectiveness. It also flags that an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Why it matters — ACRS watchers would care because the report highlights both bullish estimate-revision momentum and a consensus price target implying significant upside, offering signals about how analysts view the stock's near-term prospects.

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

GlobeNewsWire · 6 Aug 2026positive

Aclaris Therapeutics announced that the FDA granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus, including oral erosive LP, cutaneous LP, and lichen planopilaris. The company expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026.

Why it matters — Fast Track designation for modzatinib signals potential expedited development and review for a key pipeline candidate, relevant to Aclaris watchers tracking the company's immuno-inflammatory disease programs.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Aclaris Therapeutics reported a Q2 loss of $0.15 per share, which was narrower than the Zacks Consensus Estimate of a $0.16 loss but wider than the $0.13 per-share loss a year ago. The report indicates the company topped revenue estimates.

Why it matters — ACRS watchers would care because the quarterly loss came in better than analysts expected, even though it was larger than the prior-year loss.

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewsWire · 6 Aug 2026positive

Aclaris Therapeutics announced its second quarter 2026 financial results and provided a corporate and clinical update. The company reported full top-line results from the Phase 1a SAD/MAD trial of ATI-052, validating a potential best-in-class potency advantage and opportunity for extended dosing, reaffirmed timelines for upcoming top-line results from Phase 1b proof-of-concept trials of ATI-052 and the Phase 2 trial of Bosakitug (ATI-045), and stated its cash runway is expected to support pipeline development through the end of 2028.

Why it matters — ACRS watchers would follow this update because it provides validation of ATI-052's potency, reconfirms clinical trial readout timelines for key pipeline candidates, and signals financial runway through 2028.

FAQ

Frequently asked questions about ACRS stock

What is the ACRS stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Aclaris Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $4 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACRS stock a buy right now?

Of the 12 analysts covering Aclaris Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aclaris Therapeutics, Inc. 67 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACRS?

As at 12 Sept 2026, Aclaris Therapeutics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will ACRS stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +88.0% from the last close, and Ticker Nerd's factor model ranks Aclaris Therapeutics, Inc. 67 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACRS stock forecast for 2030?

No analyst covering Aclaris Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $16 over the next 12 months.

How has ACRS stock performed over the past year?

Aclaris Therapeutics, Inc. returned +170.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aclaris Therapeutics, Inc. do?

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small- and large-molecule therapies for immuno-inflammatory diseases.

What is the latest news on ACRS?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference". Aclaris Therapeutics announced that CEO Dr. Neal Walker will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 2:45 PM ET. The company is a clinical-stage biopharmaceutical firm developing product candidates for immuno-inflammatory diseases.

Company

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small- and large-molecule therapies for immuno-inflammatory diseases. The company centers its work on conditions with significant unmet medical need, using its proprietary KINect drug discovery platform and integrated research capabilities to advance product candidates through early development. Aclaris Therapeutics’ portfolio includes therapeutics aimed at inflammatory and autoimmune disorders, with programs spanning dermatology-related conditions and other immune-mediated diseases. In addition to its core therapeutics business, the company operates a contract research segment through Confluence Discovery Technologies, which provides laboratory and drug discovery services to pharmaceutical and biotechnology partners. Based in Wayne, Pennsylvania, Aclaris Therapeutics plays a specialized role in the biopharmaceutical market by combining internal drug development with research services for external collaborators.

CEO Dr. Neal S. Walker D.O., M.D. · 69 employees · United States · https://www.aclaristx.com